Found 26 Multiple Myeloma trials
A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Multi-center, open-label, first in human (FIH) Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen, TnMUC1 and activating the T cell (CARTTnMUC1 cells). …
The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) for each treatment combination (between daratumumab plus talquetamab and teclistamab plus daratumumab) and to characterize the safety of each RP2D for selected treatment combinations. Patients from within the Penn Medicine Cancer Center will be approached as potential participants.
The primary objective of this pilot study is to explore in a preliminary fashion whether administration of TAK-573 increases the number of BCMA-specific T cells in blood samples from patients with myeloma.
The purpose of this study is to see if JNJ-68284528 is safe and useful for treating patients with relapsed or refractory multiple myeloma.
The research study is being conducted to see if combining an investigational drug, called belantamab mafodotin, with standard-of-care autologous stem cell transplant and maintenance therapy in patients with myeloma can help reduce the amount of myeloma cells that can be detected in patients after transplant. We will also study if …
Please see page 4 of the attached protocol
he purpose of this expanded access program (EAP) is to provide ciltacabtagene autoleucel (cilta-cel) that does not meet the commercial release specifications of CARVYKTI and is not available via the local health care system in the country where the treatment is requested.
This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX120 in subjects with relapsed or refractory multiple myeloma.
We are doing this study to see if CAR T-cell therapy (bb2121) and maintenance therapy with the drug lenalidomide can help delay multiple myeloma from coming back.
Compassionate use access to belantamab mafodotin (GSK2857916) for eligible participants with refractory/relapsing multiple myeloma. We would like to rely on WCG as the IRB of record for this study.
